-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QL-415 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - QL-415 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. QL-415 in Solid Tumor Drug Details: QL-415 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SORC-13 in Epithelial Ovarian Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SORC-13 in Epithelial Ovarian Cancer Drug Details: SORC-13 is under development for treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Valemetostat in Cutaneous T-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Valemetostat in Cutaneous T-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Valemetostat in Cutaneous T-Cell Lymphoma Drug Details: Valemetostat tosilate (Ezharmia) is...
-
Product Insights
Colon Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colon Cancer Pipeline Products Market Report Overview Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools, and weight loss...
-
Product Insights
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Drugs Market Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation therapy....
-
Product Insights
Non-Small Cell Lung Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Small Cell Lung Cancer Pipeline Drugs Market Report Overview Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC (malignancy) originates in the tissues of the lungs or the cells lining the airways. Symptoms usually occur in the later stages of the disease, and include a persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness, and unintentional weight...
-
Product Insights
Gastrointestinal Stromal Tumor (GIST) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gastrointestinal stromal tumors (GIST) belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. Its treatment involves the use of surgery, radiation therapy, targeted therapy, and chemotherapy. The Gastrointestinal Stromal Tumor pipeline market research report provides comprehensive information on the therapeutics under development for GIST, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action...
-
Product Insights
Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Prostate cancer usually occurs in older men. Its symptoms include problems while urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips, or thighs, bone pain, and erectile dysfunction. The Prostate Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the...
-
Product Insights
Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer – Drugs In Development, 2022, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood...
-
Product Insights
Peritoneal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Peritoneal cancer develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus, and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea, and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological...